Ginera

Quick links to important sections

Ginera

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ginera

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Gestodene
Form Coated tablets
Pharmacological Class Combined Oral Contraceptive (COC)
Common Use Contraception (Birth Control)
Origin Synthetic hormones

Ginera is classified as a Combined Oral Contraceptive (COC), a prescription-only pharmaceutical product administered orally and defined by its primary purpose: contraception. Combined Oral Contraceptives utilize two types of synthetic female sex hormones.

What Type of Medicine is Ginera?

Ginera is a monophasic hormonal contraceptive, which means that every active coated tablet delivers the same, fixed dosage of hormonal ingredients throughout the treatment cycle. This places it within the broader class of synthetic hormones used to regulate fertility. The formulation is clinically recognized for providing highly reliable, reversible birth control support, distinguishing it from progestin-only pills through its use of both estrogen and progestin.

Ginera's Composition: Ethinyl Estradiol and Gestodene

The preparation is a combination product containing two International Nonproprietary Name (INN) active ingredients: Ethinyl Estradiol (the estrogen component) and Gestodene (the progestin component). Both Ethinyl Estradiol and Gestodene are synthetic steroids utilized in hormonal regulation.

What is the General Purpose of This Combination Pill?

The central purpose of Ginera is highly effective, reversible birth control. This effect is achieved through a multi-level mechanism: the synthetic hormones prevent the monthly release of an egg from the ovaries, a process known as ovulation inhibition. Additionally, the hormones cause the cervical mucus to thicken, hindering sperm movement, which defines the comprehensive nature of its pregnancy prevention mechanism.

Regulatory References

  1. MedlinePlus: Birth control pills - combination
  2. NIH: Oral Contraceptive Pills - StatPearls

What side effects are possible with Ginera?

Possible Side Effects and Safety Information

The most clinically significant safety information regarding the use of Ginera (a combined oral contraceptive containing ethinylestradiol and gestodene) is the increased risk of blood clots (thromboembolism) compared to not using a hormonal contraceptive. Although rare, these events can be serious and potentially life-threatening. They include venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as arterial thromboembolism (ATE), such as heart attack and stroke.

Serious and Clinically Significant Adverse Reactions

System-Organ Class Serious Adverse Reactions (Rare to Very Rare)
Vascular Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Heart Attack, Stroke, Retinal Vein Thrombosis (loss of vision)
Hepato-biliary Liver tumors (benign, very rarely malignant), Jaundice, Gallbladder disease
Gastrointestinal Pancreatitis (often associated with high triglycerides)

Common Adverse Reactions

Adverse effects reported more commonly include headache, nausea, abdominal pain, breast tenderness, changes in mood or depressed mood, and weight gain. Changes in menstrual bleeding patterns, such as bleeding between periods (spotting or breakthrough bleeding), may also occur, especially during the first few months of use.

Safety Restrictions and Contraindications

The medication is contraindicated (should not be used) in individuals with a current or past history of blood clots, inherited or acquired blood clotting disorders, severe uncontrolled high blood pressure, certain types of migraines with aura, or known or suspected hormone-sensitive cancers. Caution is required in women who have just given birth, those who are obese, those with severe diabetes, or those undergoing prolonged immobilization, due to the further increased risk of thromboembolism. The pill does not offer protection against sexually transmitted infections (STIs).

Overdose and Emergency Response

The official regulatory profile for Ginera establishes that an acute overdose is not likely to be life-threatening, consistent with documentation for similar combined oral contraceptives. Acute severe outcomes are considered highly unlikely following the ingestion of a large number of tablets.

Documented clinical manifestations of overdose are primarily limited to common physiological responses. These include acute gastrointestinal symptoms such as nausea and vomiting. In females and adolescents, a typical hormonal manifestation is the occurrence of vaginal bleeding, specifically termed withdrawal or breakthrough bleeding.

Despite the low severity classification, government authorities mandate specific emergency actions. In the case of suspected overdose, it is required to seek medical help right away and to call the local poison control center immediately for expert assessment.

Regulatory information confirms that no specific antidote is known for this combination of synthetic steroids. Consequently, any necessary intervention is strictly limited to providing symptomatic and supportive treatment. If emergency assessment is required, hospital monitoring may be required for observation, including the continuous assessment of vital signs such as temperature, blood pressure, and pulse. This approach is mandated to rule out any adverse events.

Therapeutic Uses of Ginera

Ginera, generally used for contraception, is considered relevant for additional symptomatic support across several key domains, including symptom management.

The combination is commonly used to help with symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort (dysmenorrhea), symptoms associated with heavy blood loss (menorrhagia), and hormone-related skin issues (acne). This application is relevant for managing symptoms that interfere with daily comfort, and may help patients cope more steadily with symptom fluctuations. The support provided contributes to improved comfort during periods of heightened symptoms, helping to ease the overall symptom burden.

“The medication supports general well-being during symptomatic phases.”


Quick Fact: Symptomatic Support Therapeutic Focus Symptoms Supported
Gynecological Symptom Management Painful periods, heavy bleeding, cycle irregularity
Dermatological Support Hormone-related mild-to-moderate acne
Primary Benefit Supports general well-being during symptomatic phases

Regulatory References

  1. European Medicines Agency overview on Combined Hormonal Contraceptives

Eligibility and Restrictions for Use

Who can and cannot use Ginera?

Ginera, a combined oral contraceptive containing the hormones ethinylestradiol and gestodene, is generally suitable for women of reproductive age seeking to prevent pregnancy. However, its use is governed by specific medical criteria to ensure safety and efficacy.

Contraindications: When Ginera Should Not Be Used

There are several conditions under which Ginera is strictly contraindicated due to increased health risks. These include, but are not limited to, the presence or history of certain serious conditions:

  • Thrombosis (blood clots) in the legs, lungs, or other parts of the body, or other conditions predisposing to clotting.
  • Migraines with aura.
  • Breast cancer or other hormone-sensitive cancers.
  • Undiagnosed vaginal bleeding.
  • Severe liver disease or liver tumors.
  • Uncontrolled hypertension (high blood pressure).
  • Diabetes with vascular complications.

Special Considerations

Use of Ginera is also not recommended during pregnancy. A healthcare provider will evaluate a patient's full medical history, including risk factors for cardiovascular disease, before prescribing this medication. Patients over 35 who smoke should typically seek alternative contraceptive methods due to significantly elevated risks.

What should I know about interactions with other medicines?

Ginera Interactions with other medicines and products

This medication is involved in documented interactions with specific classes of drugs and products, primarily through enzyme-mediated and pharmacodynamic effects.


Contraindicated Combinations

Co-administration is strictly contraindicated with the Hepatitis C virus (HCV) drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to a clinically significant risk of elevated liver enzymes (ALT).

Reduced Efficacy Interactions

Concomitant use with medicinal products that induce liver enzymes—specifically the CYP3A4 system—can significantly decrease the plasma concentrations of the contraceptive hormones (levonorgestrel and ethinylestradiol). This is associated with an increased risk of contraceptive failure and breakthrough bleeding. Examples of documented enzyme inducers include, but are not limited to, phenytoin, barbiturates, carbamazepine, rifampicin, and St. John’s Wort (Hypericum perforatum). Official regulatory guidance advises patients to use an additional non-hormonal barrier method of contraception while taking these interacting agents and for at least 28 days after stopping the enzyme inducer.

Increased Concentration Interactions

Ginera may also affect the metabolism of certain other drugs, leading to increased plasma concentrations of those co-administered agents. This applies to substrates of metabolic enzymes which may be inhibited by the contraceptive components, such as the antiepileptic drug lamotrigine, whose levels are significantly reduced, requiring dose adjustment.

Mechanism of Action

Ginera, a combination of an estrogen (ethinylestradiol) and a progestin (gestodene), exerts its pharmacodynamic effects through coordinated action on the hormonal feedback loops and target reproductive tissues.

Modulation of the Hypothalamic-Pituitary-Ovarian (HPO) Axis

The active compounds engage steroid hormone receptors in the hypothalamus and pituitary gland. This receptor binding suppresses the hypothalamic release of gonadotropin-releasing hormone (GnRH), which, in turn, modifies the pituitary's output of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This mechanistic cascade results in the modulation of gonadotropin release and suppression of the follicular maturation process.

Alterations in Cervical and Endometrial Systems

The drug concurrently acts as a receptor agonist in local reproductive tissues. This initiates signaling sequences that lead to the thickening of cervical mucus, physically impeding sperm transport. Furthermore, the active compounds affect the endometrium, modifying the molecular steps required for adequate endometrial proliferation and maturity, which results in altered endometrial morphology and function.

Dosage and Administration Information

How to Use Ginera: Administration Guidelines

Ginera, a combined oral contraceptive, is administered according to a precise, cyclical regimen to ensure continuous hormonal coverage. The usage structure is determined by the tablet composition, which delivers a fixed, monophasic dose of 75 mu g Gestodene and 30 mu g Ethinyl Estradiol per active tablet.


Administration Protocol

Feature Procedural Instruction
Administration Route Oral only, using the coated tablets.
Dosing Schedule One active tablet is taken daily for 21 consecutive days, followed by a 7-day hormone-free interval.
Timing & Frequency The tablet must be taken once daily at the same time every day to maintain consistent hormonal levels and cycle adherence.
Sequence of Intake Tablets must be consumed in the order directed by the blister packaging.

Usage Context and Special Rules

Administration of Ginera follows a long-term, cycle-after-cycle pattern for sustained contraception. The protocol outlines specific procedural considerations for initiating use in certain populations; for example, administration may be initiated no earlier than 21 to 28 days after delivery for non-breastfeeding individuals.

A critical condition for proper use is managing gastrointestinal events. If vomiting or severe diarrhoea occurs within approximately three to four hours of taking an active tablet, the necessary action depends on the elapsed time and the current week of the cycle, as this situation may affect drug absorption and is treated as a missed dose.

These guidelines establish the 28-day protocol that must be followed sequentially and on a strict daily schedule, forming the structural basis for the drug's use.

Recent Clinical Evidence

Research evidence / Overview of studies for Ginera (Ethinyl Estradiol/Gestodene)

This section provides an overview of the official research, including clinical trials and regulatory summaries, that explore the use of the combination medicine Ethinyl Estradiol and Gestodene. This summary focuses only on what the studies examined and reported, not on clinical advice or instructions for use.


Evidence for Primary Use: Contraception and Pregnancy Prevention

The primary clinical use of the combination was studied for pregnancy prevention. The evidence base includes extensive data from large-scale, multi-center Randomized Controlled Trials (RCTs) and long-term surveillance studies that enrolled thousands of healthy women of reproductive age. These studies were designed to monitor the regimen's effectiveness by measuring the Pearl Index (PI), which tracks the number of unintended pregnancies that occur per 100 women over a year of use. Reports from these evaluations described patterns related to a low measured rate of pregnancy (low PI) as observed in study participants when the regimen was used consistently in trials.

What remains uncertain is the precise degree to which real-world user adherence affects long-term effectiveness measurements across all populations.


Evidence for Symptom Management: Menstrual Cycle and Dermatological Support

Research has also explored the use of this combined oral contraceptive (COC) class in managing certain outcomes related to physical discomfort, specifically for painful periods (Dysmenorrhea) and heavy bleeding (Menorrhagia). Research examined outcomes related to discomfort and menstrual blood loss. Findings describe patterns observed in studies where patient-reported outcomes described perceived discomfort and where studies reported measurements of changes in the severity of menstrual blood loss compared to baseline.

For Hormone-Related Acne, studies enrolled women with mild-to-moderate acne and examined outcomes like changes in acne lesion counts. Research highlights changes measured during the study period, describing that measurable changes in skin-related outcomes may be observed after several months of monitoring. The research also uses data from the broader COC class to contextualize findings related to the progestin component, Gestodene.


Gaps in Evidence and Areas of Research Uncertainty

While the evidence base is strong for primary contraceptive efficacy, several limitations are noted: Comparative evidence is limited for direct, head-to-head comparisons of this specific combination against all other available COCs across every single non-contraceptive outcome (e.g., mood changes, weight patterns). Follow-up durations were limited in many non-contraceptive trials, contributing to uncertainty regarding the consistency of measured changes in symptom severity over five or more years. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Ginera (FAQ)


Q: What happens if I miss a dose of Ginera?

Official guidelines outline specific procedural steps for managing a missed tablet, which vary depending on the number of tablets missed and the timing since the last dose.

Generally, if the delay is less than 12 hours, contraceptive coverage is described as being maintained. If the delay is longer, official guidance suggests considering a barrier method for the following seven days.


Q: Is it normal to feel nauseous when starting Ginera?

Nausea is listed in regulatory documents as a common adverse reaction reported with this medication. These common reactions are often observed by users during the first few treatment cycles.

Concerns about the severity or persistence of this effect should be discussed with a healthcare provider.


Q: Can Ginera affect my ability to drive or operate machinery?

Regulatory documents indicate that no effects on the ability to drive or use machinery have been observed or specifically reported with the use of Ginera. No official warnings related to operating vehicles or heavy equipment are included in the product information.


Q: Can Ginera cause weight gain?

Weight gain is listed in official regulatory documents as one of the commonly reported adverse reactions for combined oral contraceptives like Ginera. This is based on reports received from individuals who have used the medication.


Q: Is there a generic version of Ginera available?

Ginera is a combination of two generic active ingredients: Ethinyl Estradiol and Gestodene. Products containing this specific combination of hormones are sold under various brand names and may also be available as generic formulations depending on local market regulations.


Q: Does Ginera affect the results of blood tests?

The use of combined oral contraceptives is described in official regulatory documents as potentially influencing the results of certain laboratory tests. This may include parameters related to liver, thyroid, adrenal, and renal function, as well as blood clotting factors.


Q: What is the likelihood of having a specific side effect listed for Ginera?

Official documents categorize side effects into frequency groups, such as 'very common,' 'common,' 'uncommon,' 'rare,' and 'very rare.' These categories describe the likelihood of occurrence observed in clinical studies or post-marketing surveillance.


Q: Can I take Ginera with over-the-counter pain relievers?

Regulatory-sourced interaction information indicates that the estrogen component in this contraceptive may affect the metabolism of certain other medicines, including some common non-prescription pain relievers.

Official information describes this area as one where caution is advised.


Q: Why are routine check-ups often recommended while on Ginera?

Official guidance mandates that a medical history and physical examination, including checks of blood pressure, should be conducted before starting Ginera and periodically while taking it. This ongoing monitoring is necessary due to the associated cardiovascular safety risks, particularly the risk of blood clots.


Q: How quickly does Ginera start working after I begin taking it?

If administration is initiated later than the first day of the menstrual cycle, regulatory documents state that contraceptive effectiveness should not be considered reliable right away.

Contraceptive effectiveness is described in regulatory documents as being established after the first 7 consecutive days of active tablet administration.


Q: Is Ginera safe to use if I have high blood pressure?

The official documentation lists uncontrolled high blood pressure as a contraindication for use. Official documents state that blood pressure monitoring is required for all patients, as combined oral contraceptives may cause an increase in blood pressure over time.


Q: Does alcohol interact with Ginera?

Some regulatory resources state that the central nervous system effects and blood levels of alcohol may potentially be increased when combined with oral contraceptives, although data on this specific interaction are described in some sources as contradictory.


Q: Is it possible to take Ginera long-term?

The official administration protocol outlines a continuous, cycle-after-cycle regimen for contraception. The decision to continue long-term use is based on ongoing medical evaluation of the individual's specific health and risk factors.


Q: How long does Ginera stay in your system after you stop taking it?

While the specific time for the hormones to fully clear the body is not usually stated in patient information, official documents indicate a rapid return to the natural menstrual cycle and fertility. This return to normal function is typically observed within the first few cycles after stopping the medication.


Q: Can Ginera cause problems with vision?

Official safety information lists Retinal Vein Thrombosis as a rare, serious adverse reaction associated with this class of drug. This condition is a blood clot affecting the blood vessels of the eye, which may potentially result in loss of vision.


Q: Why is Ginera only available via prescription?

Regulatory bodies classify this medication as prescription-only due to the need for mandatory medical assessment and monitoring of risk factors. This is primarily because of the associated risk of thromboembolism (blood clots), which requires clinical evaluation before use.


Q: Are there specific food or drinks that interact with Ginera?

Official administration instructions generally state that the tablets can be taken with or without food. No specific foods or drinks are listed as interacting agents in the regulatory documents that would affect the drug's effectiveness.


Q: Are there different strengths or dosages of Ginera available?

Ginera itself is defined by a fixed, monophasic dose of its two active ingredients. However, the components—Ethinyl Estradiol and Gestodene—are available in different combination strengths under various brand names on the market.


Q: Can men use Ginera for any medical reason?

The drug is officially indicated for oral hormonal contraception, and its safety and efficacy are established in adult women of reproductive age. Regulatory documents do not list any indications or established use for men.


Q: What happens when I stop taking Ginera?

The regulatory documents confirm that the cessation of the medication is followed by a return to the natural menstrual cycle and a return to fertility, which is typically observed in the cycles following discontinuation.


Q: Does sun exposure or tanning matter while using Ginera?

Official warnings state that women with a tendency to chloasma (patches of skin discoloration) should avoid prolonged exposure to direct sunlight or ultraviolet radiation while using combined oral contraceptives.


Q: Can Ginera be used by teenagers?

Official documentation states that the safety and efficacy of combined hormonal contraceptives have been established in adult women of reproductive age. Specific studies or data regarding use in the paediatric population are not available in the regulatory records.


Q: Does Ginera lose effectiveness over time?

The regimen is designed to provide sustained contraceptive protection as long as it is taken correctly according to the continuous, cycle-after-cycle administration protocol defined in the official documents. It is not described in official sources as losing effectiveness over years of use.


Q: Is Ginera used for pain relief?

Ginera is officially classified as a Combined Oral Contraceptive, and its primary purpose is contraception. While research has examined outcomes related to painful periods (dysmenorrhea), it is not classed or indicated as a pain relief medication.


Q: Does Ginera interact with antibiotics?

Official drug interaction information confirms that certain antibiotics may reduce the effectiveness of the contraceptive hormones. Official regulatory guidance describes the requirement for an additional non-hormonal barrier method during use and for a period after stopping the antibiotic.


Q: Why do some people report feeling tired after starting Ginera?

Tiredness or fatigue is listed in official documentation as an adverse effect reported by users of combined oral contraceptives. This is a common reaction that may be experienced by some individuals.


Q: Is Ginera known to cause hair loss?

Hair loss is listed in the official documentation as an uncommon adverse reaction reported with the use of this combined oral contraceptive. This finding is based on post-marketing surveillance.

How should Ginera be stored and disposed of?

Storage Conditions

Ginera coated tablets must be stored at a temperature not exceeding 30 C. To maintain product stability, the medicine must be protected from both light and moisture. For this reason, it is required to keep the tablets in the original blister pack until use.

Child Safety and Handling

All medicinal products, including Ginera, must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Ginera must be disposed of in accordance with local requirements for pharmaceutical waste. To protect the environment, the medicine must not be thrown away via household wastewater or regular household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ginera found in:

A-Z Index: